📊 PCSA Key Takeaways
Is Processa Pharmaceuticals, Inc. (PCSA) a Good Investment?
Processa Pharmaceuticals is a pre-revenue development-stage pharmaceutical company with unsustainable cash burn of $3.6M annually against only $1.7M in cash reserves, indicating less than 6 months of operational runway. With zero revenue generation, $3.3M operating losses, negative ROE (-132.9%) and severe liquidity stress (current ratio 0.98x), the company faces existential risk without successful capital raises or near-term product commercialization.
Processa Pharmaceuticals, Inc. Key Strengths (PCSA)
- Minimal debt burden with only $27.5K long-term debt and 0.01x debt-to-equity ratio provides clean balance sheet
- Low capital expenditure requirements ($3.2K) typical of pharmaceutical development-stage companies preserve cash
- Maintains $1.7M in cash reserves for ongoing operations and R&D activities
PCSA Stock Risks: Processa Pharmaceuticals, Inc. Investment Risks
- Zero revenue with $3.3M annual operating losses creates unsustainable burn profile
- Operating cash flow of -$3.6M exceeds total cash position, indicating critical liquidity crisis with <6 months runway
- Current ratio of 0.98x signals liquidity stress with current liabilities exceeding current assets
- Negative ROE (-132.9%) and ROA (-74.7%) demonstrate severe shareholder value destruction
- No disclosed revenue-generating products or clear commercialization timeline
- Dependency on capital markets access, clinical trial success, and partnership deals for survival
Key Metrics to Watch
- Monthly cash burn rate relative to remaining cash position and time to funding requirement
- Clinical trial progress, regulatory filings, and FDA pipeline advancement
- Revenue milestones and product commercialization announcements
- Capital raise announcements and cash position extensions
- Strategic partnerships, licensing deals, or acquisition interest
Processa Pharmaceuticals, Inc. (PCSA) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
PCSA Profit Margin, ROE & Profitability Analysis
PCSA vs Healthcare Sector: How Processa Pharmaceuticals, Inc. Compares
How Processa Pharmaceuticals, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Processa Pharmaceuticals, Inc. Stock Overvalued? PCSA Valuation Analysis 2026
Based on fundamental analysis, Processa Pharmaceuticals, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Processa Pharmaceuticals, Inc. Balance Sheet: PCSA Debt, Cash & Liquidity
PCSA Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Processa Pharmaceuticals, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-96.78 indicates the company is currently unprofitable.
PCSA Revenue Growth, EPS Growth & YoY Performance
PCSA Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2023 | N/A | -$2.1M | $-0.08 |
| Q2 2023 | N/A | -$2.6M | $-0.10 |
| Q1 2023 | N/A | -$3.2M | $-0.18 |
| Q3 2022 | N/A | -$2.1M | $-0.19 |
| Q2 2022 | N/A | -$2.1M | $-0.20 |
| Q1 2022 | N/A | -$2.1M | $-0.14 |
| Q3 2021 | N/A | -$733.4K | N/A |
| Q2 2021 | N/A | -$733.4K | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Processa Pharmaceuticals, Inc. Dividends, Buybacks & Capital Allocation
PCSA SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Processa Pharmaceuticals, Inc. (CIK: 0001533743)
📋 Recent SEC Filings
❓ Frequently Asked Questions about PCSA
What is the AI rating for PCSA?
Processa Pharmaceuticals, Inc. (PCSA) has an AI grade of D with 95% confidence, based on fundamental analysis of SEC EDGAR filings.
What are PCSA's key strengths?
Claude: Minimal debt burden with only $27.5K long-term debt and 0.01x debt-to-equity ratio provides clean balance sheet. Low capital expenditure requirements ($3.2K) typical of pharmaceutical development-stage companies preserve cash.
What are the risks of investing in PCSA?
Claude: Zero revenue with $3.3M annual operating losses creates unsustainable burn profile. Operating cash flow of -$3.6M exceeds total cash position, indicating critical liquidity crisis with <6 months runway.
What is PCSA's revenue and growth?
Processa Pharmaceuticals, Inc. reported revenue of $0.0.
Does PCSA pay dividends?
Processa Pharmaceuticals, Inc. pays dividends, with $0.0M distributed to shareholders in the trailing twelve months.
Where can I find PCSA SEC filings?
Official SEC filings for Processa Pharmaceuticals, Inc. (CIK: 0001533743) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is PCSA's EPS?
Processa Pharmaceuticals, Inc. has a diluted EPS of $-1.29.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is PCSA's fundamental grade?
Based on our AI fundamental analysis in June 2026, Processa Pharmaceuticals, Inc. has a D grade with 95% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is PCSA stock overvalued or undervalued?
Valuation metrics for PCSA: ROE of -132.9% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is PCSA's AI grade for 2026?
Our dual AI analysis gives Processa Pharmaceuticals, Inc. a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is PCSA's free cash flow?
Processa Pharmaceuticals, Inc.'s operating cash flow is $-3.6M, with capital expenditures of $3.2K.
How does PCSA compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -132.9% (avg: 15%), current ratio 0.98 (avg: 2).